SCHEMBL20375605

SCHEMBL20375605

COP(C)(=O)OCCOCCOCCOCCOCCC(=O)NC(CCC(=O)NC(CCC(=O)NCCOCCON)C(=O)NCCOCCON)C(=O)NCCOCCON

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 8/20 0.47
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ LPAR3 Q9UBY5 4/20 0.34
▸ PLG P00747 1/20 0.33
▸ PRSS1 P07477 1/20 0.33
▸ PRSS2 P07478 1/20 0.33
▸ PRSS3 P35030 1/20 0.33
▸ TPSAB1 Q15661 1/20 0.33
▸ TLR2 O60603 3/20 0.33
▸ NMT2 O60551 1/20 0.32
▸ NMT1 P30419 1/20 0.32
▸ LPAR1 Q92633 2/20 0.31
▸ CHRNA1 P02708 1/20 0.31
▸ CHRNG P07510 1/20 0.31
▸ CHRNB1 P11230 1/20 0.31
▸ CHRND Q07001 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20017564 0.89 GLP1R (0.46) GLP1RMEN1KMT2ALPAR3PLG
SCHEMBL20375472 0.88 GLP1R (0.46) GLP1RMEN1KMT2ALPAR3PLG
SCHEMBL23714584 0.87 GLP1R (0.46) GLP1RMEN1KMT2ALPAR3TLR2
SCHEMBL20814382 0.85 GLP1R (0.47) GLP1RMEN1KMT2ALPAR3TLR2
SCHEMBL21287433 0.84 GLP1R (0.46) GLP1RMEN1KMT2ALPAR3PLG
SCHEMBL22566714 0.84 GLP1R (0.44) GLP1RMEN1KMT2ALPAR3TLR2
SCHEMBL18715477 0.84 GLP1R (0.47) GLP1RMEN1KMT2ALPAR3TLR2
SCHEMBL18715474 0.84 GLP1R (0.47) GLP1RMEN1KMT2ALPAR3TLR2
SCHEMBL22566694 0.83 GLP1R (0.44) GLP1RMEN1KMT2ALPAR3PLG
SCHEMBL18715473 0.83 GLP1R (0.46) GLP1RMEN1KMT2ALPAR3TLR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210238602-A1 RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT 2021-08-05 — — US disclosed
US-10662427-B2 Compositions and methods for inhibiting gene expression of LPA Arrowhead Pharmaceuticals, Inc. (US) 2020-05-26 — — US disclosed
US-20180195070-A1 Compositions and Methods for Inhibiting Gene Expression of LPA Arrowhead Pharmaceuticals, Inc. 2018-07-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238602-A1 RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use TEK, PLIN3, PNLIP GLP1R 459/4885MEN1 2902/4885KMT2A 2388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback